Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data (Q30817255)

26 June 2017

1 reference

title

Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data (English)

1 reference

26 June 2017

Fredenrich A

1

1 reference

26 June 2017

Bayer P

series ordinal

2

1 reference

26 June 2017

publication date

1 June 2003

1 reference

26 June 2017

published in

Diabetes and Metabolism

1 reference

26 June 2017

volume

29

1 reference

26 June 2017

issue

3

1 reference

26 June 2017

page(s)

201-205

1 reference

High-density lipoprotein--the clinical implications of recent studies

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Atheroprotective mechanisms of HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Prevalence of risk factors in men with premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

HDL and arteriosclerosis: beyond reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Increase in body fatness as a major determinant of changes in serum total cholesterol and high density lipoprotein cholesterol in young men over a 10-year period

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Currently available hypolipidaemic drugs and future therapeutic developments

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

Activation of PPARdelta alters lipid metabolism in db/db mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970029-0

7 January 2021

10.1016/S1262-3636(07)70029-0

Identifiers

DOI

1 reference

26 June 2017

1 reference